A systematic review was conducted to illustrate the bleeding risks associated with targeted therapies used in the treatment of metastatic renal cell carcinoma (mRCC). Eligible studies included phase II, III, or IV clinical trials using pazopanib, sunitinib, cabozantinib, lenvatinib, everolimus, temsirolimus, bevacizumab, axitinib, and/or sorafenib in the setting of mRCC. Types of bleeding event(s), bleeding event frequency, and incidence of thrombocytopenia were collected from the relevant articles. ClinicalTrials.gov was also searched for incidence of "Serious bleeding adverse effects" reported in these trials. The incidences of bleeding events ranged from 1 to 36%, and incidences of thrombocytopenia ranged from 2 to 78%. Available serious bleeding adverse events ranged from 1 to 7%. The highest percentage of bleeding incidences were seen with bevacizumab, while the lowest percentage of bleeding incidences were seen with axitinib. All of the included trials were of high quality per Jadad scoring.
Critical reviews in oncology/hematology. 2017 Nov 01 [Epub]
MacKenzie Crist, Elizabeth Hansen, Lipika Chablani, Elizabeth Guancial
Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY, United States., Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States., Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY, United States. Electronic address: .